CL2016000915A1 - Use of a composition comprising at least one humanized monoclonal antibody or neutralizing molecules that neutralize the function of the tslp and / or tslpr and / or ox40l and / or cd177 molecules, to prepare a medicament for the treatment or to lessen the symptoms and disease of patients infected with human metapneumovirus (hmpv) - Google Patents
Use of a composition comprising at least one humanized monoclonal antibody or neutralizing molecules that neutralize the function of the tslp and / or tslpr and / or ox40l and / or cd177 molecules, to prepare a medicament for the treatment or to lessen the symptoms and disease of patients infected with human metapneumovirus (hmpv)Info
- Publication number
- CL2016000915A1 CL2016000915A1 CL2016000915A CL2016000915A CL2016000915A1 CL 2016000915 A1 CL2016000915 A1 CL 2016000915A1 CL 2016000915 A CL2016000915 A CL 2016000915A CL 2016000915 A CL2016000915 A CL 2016000915A CL 2016000915 A1 CL2016000915 A1 CL 2016000915A1
- Authority
- CL
- Chile
- Prior art keywords
- molecules
- tslpr
- hmpv
- tslp
- ox40l
- Prior art date
Links
- 241000342334 Human metapneumovirus Species 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- 101150050722 Crlf2 gene Proteins 0.000 title 1
- 101100371162 Mus musculus Tslp gene Proteins 0.000 title 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 abstract 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 abstract 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 1
- 108010042215 OX40 Ligand Proteins 0.000 abstract 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al uso de una composición farmacéutica que comprende al menos un anticuerpo monoclonal humanizado o moléculas neutralizantes que neutralizan la función de las moléculas TSLP y/o TSLPR y/o OX40L y/o CD177, que sirve para preparar un medicamento para el tratamiento o para aminorar los síntomas y enfermedad de pacientes infectados con el metapneumovirus humano (hMPV).The present invention relates to the use of a pharmaceutical composition comprising at least one humanized monoclonal antibody or neutralizing molecules that neutralize the function of the TSLP and / or TSLPR and / or OX40L and / or CD177 molecules, which serves to prepare a medicament for the treatment or to reduce the symptoms and disease of patients infected with human metapneumovirus (hMPV).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2016000915A CL2016000915A1 (en) | 2016-04-15 | 2016-04-15 | Use of a composition comprising at least one humanized monoclonal antibody or neutralizing molecules that neutralize the function of the tslp and / or tslpr and / or ox40l and / or cd177 molecules, to prepare a medicament for the treatment or to lessen the symptoms and disease of patients infected with human metapneumovirus (hmpv) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2016000915A CL2016000915A1 (en) | 2016-04-15 | 2016-04-15 | Use of a composition comprising at least one humanized monoclonal antibody or neutralizing molecules that neutralize the function of the tslp and / or tslpr and / or ox40l and / or cd177 molecules, to prepare a medicament for the treatment or to lessen the symptoms and disease of patients infected with human metapneumovirus (hmpv) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000915A1 true CL2016000915A1 (en) | 2016-11-11 |
Family
ID=65629044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000915A CL2016000915A1 (en) | 2016-04-15 | 2016-04-15 | Use of a composition comprising at least one humanized monoclonal antibody or neutralizing molecules that neutralize the function of the tslp and / or tslpr and / or ox40l and / or cd177 molecules, to prepare a medicament for the treatment or to lessen the symptoms and disease of patients infected with human metapneumovirus (hmpv) |
Country Status (1)
| Country | Link |
|---|---|
| CL (1) | CL2016000915A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12178911B2 (en) | 2019-10-28 | 2024-12-31 | Medimmune Limited | Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of use thereof |
-
2016
- 2016-04-15 CL CL2016000915A patent/CL2016000915A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12178911B2 (en) | 2019-10-28 | 2024-12-31 | Medimmune Limited | Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000133A (en) | ANTIBODY PD-1, FRAGMENT OF UNION TO THE ANTIGEN OF THIS AND MEDICAL USE OF THIS | |
| ECSP18005520A (en) | FACTOR XI ANTIBODIES AND METHODS OF USE | |
| JOP20170004B1 (en) | Anti-N3pGlu anti-amyloid beta-peptide antibody and its uses | |
| CL2017001610A1 (en) | Human antibodies to influenza hemagglutinin | |
| BR112018014016A2 (en) | combination of an ox40 agonist and a 4-1bb monoclonal antibody agonist for cancer treatment | |
| BR112013004056B8 (en) | HUMAN-PROJECTED AB ANTI-N3PGLU MONOCLONAL ANTIBODIES, THEIR USE AND PHARMACEUTICAL COMPOSITION INCLUDING THEM | |
| BR112017021245A2 (en) | ANTI-C-MET ANTIBODY AND CONJUGATE ANTI-C-MET ANTIBODY CYTOXOTIC AND PHARMACEUTICAL USE OF THE SAME | |
| EA201991005A1 (en) | ANTIBODIES AND POLYPEPTIDES AIMED AGAINST CD127 | |
| ECSP10010322A (en) | ANTIBODIES AGAINST THE INFLUENZA VIRUS AND METHODS OF USE OF THE SAME | |
| UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER | |
| MX2018015350A (en) | Anti-gitr antibodies and uses thereof. | |
| CL2024000459A1 (en) | Tubulysins and protein-tubulysin conjugates. | |
| BR112015030356A2 (en) | methods of treatment of a taupathy | |
| UY37449A (en) | ANTI-CHIKV ANTIBODIES AND USES OF THESE | |
| EA201991511A1 (en) | GREMLIN-1 CRYSTAL STRUCTURE AND AN INHIBITING ANTIBODY | |
| MX378749B (en) | AGENTS FOR INFLUENZA NEUTRALIZATION. | |
| MX2022011972A (en) | COMPOSITIONS COMPRISING ANTIBODIES AGAINST IL6R FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA, AND METHODS OF USE THEREOF. | |
| MX2018013172A (en) | METHODS FOR THE TREATMENT OF DISEASES IN WHICH THE ACTIVITY OF IL-13 IS HARMFUL, THROUGH THE USE OF ANTI-IL-13 ANTIBODIES. | |
| MX2019007107A (en) | ANTI-ADRENOMEDULIN ANTIBODY (ADM) OR ANTI-ADM ANTIBODY FRAGMENT OR SUPERCONTIGO WITHOUT ANTI-ADM IG FOR USE IN INTERVENTION AND CONGESTION THERAPY IN A PATIENT IN NEED OF THE SAME. | |
| BR112018015090A2 (en) | Thrombin antibody, antigen-binding fragment thereof and pharmaceutical use | |
| UY37082A (en) | SPECIFIC MONOCLONAL ANTIBODIES FOR THE HUMAN ADENOVIRUS PIII ANTIGEN (ADV), PRODUCED AND SECRETED BY CELLULAR HYBRIDOMES, USEFUL FOR DETECTION AND DIAGNOSIS OF THE INFECTION CAUSED BY ADV | |
| GT201300058A (en) | ANTI-VEGFR-3 ANTIBODY COMPOSITIONS | |
| CL2022002404A1 (en) | Anti-gitr antibodies and their uses | |
| UY36540A (en) | HUMAN MONOCLONAL ANTIBODIES WITH STRONG NEUTRALIZING ACTIVITY AGAINST SIMPLE HERPES VIRUSES TYPE 1 (HSV-1) AND TYPE 2 (HSV-2) | |
| CL2014003373A1 (en) | Monoclonal antibodies specific for the human metapneumovirus virus (hmpv) m antigen, produced and secreted by cellular hybridomas, useful for the detection and diagnosis of hmpv infection. |